Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018)

Dee Shortridge; Cecilia G Carvalhaes; Jennifer M Streit; Robert K Flamm

doi:10.1016/j.diagmicrobio.2020.115302

Back

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018)

Journal article

Peer reviewed

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018)

Dee Shortridge, Cecilia G Carvalhaes, Jennifer M Streit and Robert K Flamm

Diagnostic microbiology and infectious disease, Vol.100(1), pp.115302-115302

05/2021

DOI: 10.1016/j.diagmicrobio.2020.115302

PMID: 33516987

View Online

Abstract

Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. Ceftolozane/tazobactam has been approved in >60 countries for treating complicated urinary tract infections, acute pyelonephritis, complicated intra-abdominal infections (with metronidazole), and hospital-acquired pneumonia, including ventilator-associated pneumonia in adults. We analyzed susceptibilities for 35,882 gram-negative isolates collected from patients in 35 US medical centers from 2012 to 2018. The rate of multi-drug resistant Enterobacterales was stable (9.5%-10.1%), while the P. aeruginosa multi-drug resistance rate increased from 15.5% in 2012 to 22.9% in 2018. The carbapenem-resistant Enterobacterales rates varied from 0.9% to 2.2% and extended-spectrum β-lactamase phenotypes increased from 10.5% to 16.8%. The most active drugs against P. aeruginosa were ceftolozane/tazobactam (95.8%-97.5% susceptible) and amikacin (93.9%-98.0%); against Enterobacterales, amikacin (97.9%-98.8%), meropenem (97.7%-98.8%), and ceftolozane/tazobactam (93.3%-95.6%) were the most active. These data suggest that ceftolozane/tazobactam has effective in vitro activity against organisms causing serious gram-negative infections.

Ceftolozane/Tazobactam

Enterobacterales

Surveillance

P. aeruginosa

Details

Title: Subtitle: Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018)
Creators: Dee Shortridge - JMI Laboratories
Cecilia G Carvalhaes - JMI Laboratories
Jennifer M Streit - JMI Laboratories
Robert K Flamm - JMI Laboratories
Resource Type: Journal article
Publication Details: Diagnostic microbiology and infectious disease, Vol.100(1), pp.115302-115302
DOI: 10.1016/j.diagmicrobio.2020.115302
PMID: 33516987
ISSN: 0732-8893
eISSN: 1879-0070
Grant note: DOI: 10.13039/100004334, name: Merck
Language: English
Date published: 05/2021
Academic Unit: Pathology
Record Identifier: 9984183991602771

Metrics

10 Record Views

11 Times Cited - Web of Science

See more details